EUVIMEDEUVIMED entdecken
Crossref

Optimizing lipid management—impact of the COVID 19 pandemic upon cardiovascular risk in England

Julia L Newton, Joseph Hamed, Helen Williams, Matt Kearney, Alison M Metcalfe, Gary A Ford

British Medical Bulletin · 2023

DOI: 10.1093/bmb/ldad009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Medical Bulletin, 2023. Verfasst von Julia L Newton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical Sciences, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 4LP, UK. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background We sought to understand the impact of the COVID-19 pandemic on lipid-lowering therapy prescribing as a potential cause of the excess cardiovascular mortality seen post-pandemic in England. We examined temporal changes over 3 years in the prescribing of high-intensity and non-high-intensity statin therapy and ezetimibe. Sources of data We utilized data available via the National Health Service (NHS) Business Services Authority (NHSBSA) Information Services Data Warehouse, extracting 3 monthly data from October 2018 to December 2021 on high- and low-intensity statin and ezetimibe prescribing, (commencement, cessation or continuation) through each time period of study and those before, and after, the period of interest. Areas of agreement Optimizing lipid management is a key component of the NHS Long Term Plan ambition to reduce deaths from cardiovascular disease, stroke and dementia. Areas of controversy The COVID-19 pandemic and associated lockdown have seen a significant reduction in prescribing of lipid-lowering therapies. If cardiovascular risk is not to worsen in the forthcoming years, urgent action is needed to ensure that the impact of the pandemic upon optimization of cholesterol and the historical undertreatment of cholesterol is reversed and improved. Areas timely for developing research Prescription data available via NHSBSA can support our understanding of the implications of policy and behaviour and highlight the impact of guidelines in practise. Growing points Understanding the impact of the COVID-19 pandemic upon cholesterol management and the opportunities for newer lipid-lowering therapies delivered using a population health approach have the potential to enhance lipid-lowering and improve cardiovascular mortality and morbidity and reduce health inequalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesCOVID-19HumansState MedicinePandemicsRisk FactorsCommunicable Disease ControlEzetimibeCholesterolHeart Disease Risk Factors

Stichwörter der Autor:innen

cardiovascular riskcholesterol managementezetimibeprescriptionsstatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeCholesterol

Autor:innen und Institutionen

  • Faculty of Medical Sciences, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne NE1 4LP, UK.
  • AHSN NENC, Academic Health Science Network for North East North Cumbria, Room 2.13, Biomedical Research Building, Campus for Ageing and Vitality, Nuns' Moor Road, Newcastle upon Tyne NE4 5PL, UK.
  • NHS Business Services Authority, Stella House, Goldcrest Way, Newburn Riverside Park, Newcastle upon Tyne NE15 8NY, UK.
  • UCLPartners, 3rd Floor, 170 Tottenham Court Road, London W1T 7HA, UK.
  • Radcliffe Department of Medicine, Division of Medical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK.
  • Oxford Academic Health Science Network, The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK.

Zitieren

APA

Newton, J. L., Hamed, J., Williams, H., Kearney, M., Metcalfe, A. M., & Ford, G. A. (2023). Optimizing lipid management—impact of the COVID 19 pandemic upon cardiovascular risk in England. British Medical Bulletin. https://doi.org/10.1093/bmb/ldad009

Vancouver

Newton JL, Hamed J, Williams H, Kearney M, Metcalfe AM, Ford GA. Optimizing lipid management—impact of the COVID 19 pandemic upon cardiovascular risk in England. British Medical Bulletin. 2023. doi:10.1093/bmb/ldad009

BibTeX
@article{Newton2023,
  author = {Newton, Julia L and Hamed, Joseph and Williams, Helen and Kearney, Matt and Metcalfe, Alison M and Ford, Gary A},
  title = {Optimizing lipid management—impact of the COVID 19 pandemic upon cardiovascular risk in England},
  journal = {British Medical Bulletin},
  year = {2023},
  doi = {10.1093/bmb/ldad009}
}
Kostenlos starten →